^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Fyarro (nanoparticle albumin-bound rapamycin) (mTORC1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.
Published date:
05/28/2020
Excerpt:
Among 18 evaluable pts, best response was: 7/18 (39%) partial response, 10/18 (56%) stable disease, and 16/18 (89%) had tumor shrinkage. PTEN was assessed in 14 pts: 4/14 (29%) had PTEN loss, 2/4 (50%) PTEN loss pts responded...The RP2D of nab-sirolimus is 20mg/m2 q2w in combination with standard mFOLFOX+bevacizumab.
Secondary therapy:
Modified FOLFOX6
DOI:
10.1200/JCO.2020.38.15_suppl.e16050
Trial ID:
